Evidence map›Paper›PMID 41282081›Full record

ArticleResearch square2025

IFN-I-Mediated Transcriptional Reprogramming Drives Myeloid-skewed Hematopoiesis in Sickle Cell Anemia.

Marion Serra, Marine Aglave, Mohammad Salma, Steven Akkaya, Patricia Hermand, Carine Lefevre, Romain Duval, Jade Merrer, Fallou Leye, Joelle Magne and 5 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Marion SerraUniversité Paris Cité, INSERM.
Marine AglaveGustave Roussy, Plateforme de bioinformatique.
Mohammad SalmaIGMM, Univ Montpellier, CNRS.
Steven AkkayaUniversité Paris Cité, INSERM.
Patricia HermandUniversité Paris Cité, INSERM.
Carine LefevreUniversité Paris Cité, INSERM.
Romain DuvalUniversité Paris Cité, INSERM, EFS.
Jade MerrerUnité d'Epidémiologie Clinique, INSERM CIC 1426.
Fallou LeyeUnité d'Epidémiologie Clinique, INSERM CIC 1426.
Joelle MagneUniversité Paris Cité, INSERM.
Isabelle PloInserm UMR 1287, Université Paris Saclay.
Lionel BlancInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, Northwell.
Eric SolerIGMM, Univ Montpellier, CNRS.
Slim AzouziUniversité Paris Cité, INSERM, EFS.
Berengere KoehlSickle Cell Disease Center, Hematology Unit, Hôpital Robert Debré, Assistance Publique - Hôpitaux de Paris.

Funding

Cellular and Molecular Control of Normal and Disordered ErythropoiesisR35HL171168 · NHLBI · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI Lionel Blanc · 2024 to 2026
$2.6M
NHLBI NIH HHS R35 HL171168
6 · The paper itself

Abstract

Neutrophils and monocytes are persistently elevated in sickle cell anemia (SCA), yet the intrinsic mechanisms driving pathological myelopoiesis and inflammation remain poorly defined. Through single-cell RNA sequencing and functional assays, we demonstrate that hematopoietic stem and multipotent progenitor cells (HSPCs) in SCA are transcriptionally reprogrammed toward myeloid differentiation. This process is orchestrated by aberrant activation of type I interferon (IFN-I) signaling, which promotes premature myeloid commitment of hematopoietic stem cells. SCA progenitors further exhibit unexpected responsiveness to granulocyte colony-stimulating factor (G-CSF) through upregulation of CSF3R, resulting in skewed myelopoiesis toward the monocytic lineage. Importantly, hydroxyurea treatment attenuates IFN-I signaling in neutrophils, consistent with its therapeutic role in reducing excessive inflammation and granulopoiesis. Collectively, these findings uncover IFN-I-driven remodeling of hematopoiesis as a fundamental mechanism of leukocytosis and chronic inflammation in SCA, and establish a tractable therapeutic axis to mitigate innate immunity activation in this disease.

Indexed as

InflammationInterferonMyelopoiesisSickle Cell Anemia

Identifiers

PMID41282081
PMCPMC12632579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.